In-silico identification and functional characterization of common genes associated with type 2 diabetes and hypertension

Type 2 diabetes (T2D) and hypertension are global public health concerns and major metabolic disorders in humans. Experimental evidence indicates considerable hereditary influences on the etiology of T2D and hypertension, but the molecular basis of these diseases is still limited. Thus, the current...

Full description

Saved in:
Bibliographic Details
Published inHeliyon Vol. 10; no. 16; p. e36546
Main Authors Rabby, Md. Golam, Suzauddula, Md, Hasan, Md. Sakib, Dewan, Mahbubur Alam, Islam, Md. Numan
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 30.08.2024
Elsevier
Subjects
Diabetes
Genetic marker
GWAS
Hypertension
Pathophysiology
Hypertension
GWAS
Diabetes
Pathophysiology
Genetic marker
Online AccessGet full text

Cover

More Information
Summary:Type 2 diabetes (T2D) and hypertension are global public health concerns and major metabolic disorders in humans. Experimental evidence indicates considerable hereditary influences on the etiology of T2D and hypertension, but the molecular basis of these diseases is still limited. Thus, the current study analyzed 185 (132 T2D and 53 hypertension) GWAS catalog datasets and identified 83 common genes linked to T2D and hypertension pathogenesis. These genes were further examined using various bioinformatics approaches to elucidate their molecular mechanisms underlying the pathophysiology of T2D and hypertension. Gene ontology (GO) analysis revealed the biological, cellular, and molecular functions of these genes, which were also linked to different T2D and hypertension pathways. Specifically, seven genes were found to be crucial for T2D, and nine were directly associated with hypertension. Protein-protein interaction (PPI) analysis identified 28 candidate genes and seven hub genes through 11 topological methods. Among 231 miRNAs, seven were significant in interacting with the hub genes, and nine transcription factors (TFs) out of 36 were linked to these hub genes. Additionally, two of the seven hub genes were downregulated by 43 FDA-approved drugs. These findings elucidate the molecular processes underlying T2D and hypertension, suggesting that targeting these genes could lead to future drug development and therapeutic strategies to treat T2D and hypertension.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed to this work equally.
ISSN:2405-8440
2405-8440
DOI:10.1016/j.heliyon.2024.e36546